Thermo Fisher Scientific’s Recent System Launches
Thermo Fisher Scientific continues to invest significantly in research and development as well as developing commercial capabilities, making the company one of the major medical technology players in the United States. The company aims to provide differentiated offerings to customers in order to provide a unique value proposition and a comprehensive portfolio of services.
Interested in TMO? Don't miss the next report.
Receive e-mail alerts for new research on TMO
Nexsa surface analysis system
On September 25, Thermo Fisher Scientific (TMO) announced the launch of its new Nexsa surface analysis system. Multiple analysis techniques can be easily integrated into a single surface analysis instrument that’s compact and fully automated.
The system should help enable cost-effective XPS (x-ray photoelectron spectroscopy) studies from academicians as well as corporate laboratories.
Expansion across Plasmid DNA Purification Portfolio
On September 26, Thermo Fisher Scientific announced the launch of its new “PureLink Fast Low-Endotoxin Plasmid Purification Midi and Maxi Kits.” This product is the latest addition to the company’s line of low-endotoxin plasmid DNA isolation products. In comparison to the current standard protocols, the new kits offer accelerated plasmic DNA isolation. Researchers are able to carry out the isolation procedure in half an hour, which reflects high yields of DNA in much less time.
According to Jeff Franz, general manager of sample preparation at Thermo Fisher Scientific, “We are committed to accelerating our customers’ journey to discovery and are excited that we can now offer customers a complete portfolio of low-endotoxin plasmid DNA isolation kits for a wide range of applications. The latest offering in our portfolio of plasmid DNA isolation kits offers researchers a protocol for protein expression that is simple, prompt and reliable. With a streamlined purification process, researchers can focus on higher-value activities – such as vaccine development, gene therapy, and genome engineering.”
Agilent (A), Abbott Laboratories (ABT), and Illumina (ILMN) are some of the major companies that offer competing products. Investors can consider the industry-focused Vanguard Health Care ETF (VHT), which invests approximately 2.04% of its total holdings in TMO.